Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Peanut Hypersensitivity: early-phase trial registry
1 of 4 indexed Peanut Hypersensitivity trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Peanut Hypersensitivity: 4 US clinical trials tracked, 1 recruiting.
Peanut Hypersensitivity is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Aravax Pty, running 1 of these trials.
Enrollment posture brief
Registry condition peanut-hypersensitivity
OPEN 1 | RECR 25% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Peanut Hypersensitivity lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Peanut Hypersensitivity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Peanut Hypersensitivity is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Rima Rachid
NCT05695261
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Aravax Pty
NCT05621317
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
Johns Hopkins University
NCT01084174
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
University of North Carolina, Chapel Hill
NCT00932282
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Peanut Hypersensitivity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Peanut Hypersensitivity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Peanut Hypersensitivity page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Peanut Hypersensitivity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Aravax Pty sponsors the most Peanut Hypersensitivity trials on record, review their full trial history before evaluating a specific study. See Aravax Pty's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peanut Hypersensitivity condition card totals 4 registered trials; most-linked intervention Placebo powder; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.